Center for Drug and Alcohol Programs, Department of Psychiatry, Medical University of South Carolina, 67 President Street, MSC 861, Charleston, SC 29425, USA.
Eur J Pharmacol. 2010 Aug 10;639(1-3):47-58. doi: 10.1016/j.ejphar.2010.01.029. Epub 2010 Apr 2.
Glutamate plays a pivotal role in regulating drug self-administration and drug-seeking behavior, and the past decade has witnessed a substantial surge of interest in the role of Group I metabotropic glutamate receptors (mGlu(1) and mGlu(5) receptors) in mediating these behaviors. As will be reviewed here, Group I mGlu receptors are involved in normal and drug-induced synaptic plasticity, drug reward, reinforcement and relapse-like behaviors, and addiction-related cognitive processes such as maladaptive learning and memory, behavioral inflexibility, and extinction learning. Animal models of addiction have revealed that antagonists of Group I mGlu receptors, particularly the mGlu(5) receptor, reduce self-administration of virtually all drugs of abuse. Since inhibitors of mGlu5 receptor function have now entered clinical trials for other medical conditions and appear to be well-tolerated, a key question that remains unanswered is - what changes in cognition are produced by these compounds that result in reduced drug intake and drug-seeking behavior? Finally, in contrast to mGlu(5) receptor antagonists, recent studies have indicated that positive allosteric modulation of mGlu(5) receptors actually enhances synaptic plasticity and improves various aspects of cognition, including spatial learning, behavioral flexibility, and extinction of drug-seeking behavior. Thus, while inhibition of Group I mGlu receptor function may reduce drug reward, reinforcement, and relapse-related behaviors, positive allosteric modulation of the mGlu5 receptor subtype may actually enhance cognition and potentially reverse some of the cognitive deficits associated with chronic drug use.
谷氨酸在调节药物自我给药和觅药行为方面发挥着关键作用,在过去的十年中,人们对 I 组代谢型谷氨酸受体(mGlu(1)和 mGlu(5)受体)在介导这些行为中的作用产生了浓厚的兴趣。正如这里将回顾的那样,I 组 mGlu 受体参与正常和药物诱导的突触可塑性、药物奖赏、强化和类似复发的行为以及与成瘾相关的认知过程,如适应不良的学习和记忆、行为灵活性和消退学习。成瘾动物模型表明,I 组 mGlu 受体拮抗剂,特别是 mGlu(5)受体,可减少几乎所有滥用药物的自我给药。由于 mGlu5 受体功能抑制剂现已进入其他医疗条件的临床试验,且似乎耐受性良好,因此仍有一个关键问题尚未得到解答 - 这些化合物会导致认知发生哪些变化,从而减少药物摄入和觅药行为?最后,与 mGlu(5)受体拮抗剂相反,最近的研究表明,mGlu(5)受体的正变构调制实际上增强了突触可塑性,并改善了各种认知方面,包括空间学习、行为灵活性和药物觅药行为的消退。因此,尽管抑制 I 组 mGlu 受体功能可能会降低药物奖赏、强化和复发相关行为,但 mGlu5 受体亚型的正变构调制实际上可能会增强认知,并可能逆转与慢性药物使用相关的一些认知缺陷。